WCG has announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is introducing a redesigned version of its Fox Trial Finder clinical study matching tool powered by WCG CenterWatch iConnect. Use of the iConnect platform will aim to make it easier for people with Parkinson’s disease (PD) and healthy volunteers to both find and participate in clinical trials.
“We are proud to be accelerating research and moving our mission forward to get safer, more effective treatments into the hands of patients living with Parkinson’s disease as efficiently as possible while maintaining the highest quality and ethical research standards. MJFF’s decision to redesign its new Fox Trial Finder on our iConnect platform will make clinical research much more accessible and easier to navigate for patients and their families,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG.
“At the Foundation our single, urgent goal is to eliminate Parkinson’s disease. It will take the efforts of all of us to better connect the millions impacted by the disease worldwide to opportunities that could advance breakthroughs in treatments and ultimately a cure,” said MJFF Deputy CEO Sohini Chowdhury. “With 85 percent of trials facing delays and 30 percent never getting off the ground due to a lack of volunteers, the new Fox Trial Finder will reduce the burden of clinical trial recruitment by connecting patients and families to trials that urgently need them.”
WCG CenterWatch iConnect is visited by more than 250,000 unique users per month, who are searching for information about clinical trials for which they, a friend or family member may qualify.
WCG CenterWatch iConnect provides advanced trial listing technology for the largest patient advocacy groups in the world. It also allows sponsors to set up and manage all aspects of their patient recruitment programs from a single platform across the enterprise. This increased visibility enables them to determine the ROI and effectiveness of each tactic they employ across every study, improving predictability and reducing outreach expense.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.